Data/hora: 05/06/2024 16:05:23

Provedor de dados: 	55	
País: 	Brazil	
Título: 	A meta-analysis of efﬁcacy and safety of doripenem for treating bacterial infections	
Autores: 	Qu,Xiao-Yu; Hu,Ting-Ting; Zhou,Wei.	
Data: 	2015-04-01	
Ano: 	2015	
Palavras-chave: 	Doripenem Meta-analysis Efﬁcacy; Safety; Infection.	
Resumo: 	Objective: The aim of this article is to compare the efﬁcacy and safety of doripenem for bacterial infections.  Methods: We included six randomized clinical trials identiﬁed from PubMed and Embase up to July 31, 2014. The included trials compared efﬁcacy and safety of doripenem for complicated intra-abdominal infections, complicated urinary tract infection, nosocomial pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the statistical software of Review Manager, version 5.2.  Results: Compared with empirical antimicrobial agents on overall treatment efﬁcacy, doripenem was associated with similar clinical and microbiological treatment success rates (for the clinical evaluable population, odds ratio [OR] = 1.26, 95% conﬁdence interval [CI] 0.93-1.69, p = 0.13; for clinical modiﬁed intent-to-treatment population, OR = 0.88, 95% CI 0.55-1.41, p = 0.60; for microbiology evaluable population, OR = 1.16, 95% CI 0.90-1.50, p = 0.26; for microbiological modiﬁed intent-to-treatment (m-mITT), OR = 0.98, 95% CI 0.81-1.20, p = 0.87). We compared incidence of adverse events and all-cause mortality to analyze treatment safety. The outcomes suggested that doripenem was similar to comparators in terms of incidence of adverse events and all-cause mortality on modiﬁed intent-to-treatment population (for incidence of AEs, OR = 1.10, 95% CI 0.90-1.35, p = 0.33; for all-cause mortality, OR = 1.08, 95% CI 0.77-1.51, p = 0.67). In nosocomial pneumonia and ventilator-associated pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of efﬁcacy and safety.  Conclusion: From this meta-analysis, we can conclude that doripenem is as valuable and well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infections, complicated urinary tract infection, acute biliary tract infection and nosocomial pneumonia treatment.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702015000200156	
Editor: 	Brazilian Society of Infectious Diseases	
Relação: 	10.1016/j.bjid.2014.10.010	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Infectious Diseases  v.19 n.2 2015	
Fonte: 	info:eu-repo/semantics/openAccess